NeuroGenetic Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:NeuroGenetic Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10697
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NeuroGenetic Pharmaceuticals Inc (NeuroGenetic Pharmaceuticals) is a pharmaceutical company that develops drugs for Alzheimer’s diseases. The company develops products with its gamma-secretase modulators technology. It applies multiple lead compounds for the treatment of neurodegenerative conditions, their composition, mechanism of action, and method of treatment. NeuroGenetic Pharmaceuticals’ NGP 555 is used to treat amyloid-based diseases such as cerebral vascular dementia, inclusion body myositis, Alzheimer’s dementia associated with down’s syndrome patients, and others. The company also offers preventative treatment on the diagnosis of amyloid plaque pathology before dementia. NeuroGenetic Pharmaceuticals is headquartered in San Diego, California, the US.

NeuroGenetic Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
NeuroGenetic Pharma Raises USD0.5 Million in Venture Financing 10
NeuroGenetic Pharma Raises US$0.1 Million In Venture Financing 11
NeuroGenetic Pharma Raises USD0.1 Million in Venture Financing 12
NeuroGenetic Pharma Raises US$0.2 Million In Venture Financing 13
NeuroGenetic Pharma Secures Investment In Venture Financing 14
NeuroGenetic Pharmaceuticals Inc – Key Competitors 15
NeuroGenetic Pharmaceuticals Inc – Key Employees 16
NeuroGenetic Pharmaceuticals Inc – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NeuroGenetic Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
NeuroGenetic Pharma Raises USD0.5 Million in Venture Financing 10
NeuroGenetic Pharma Raises US$0.1 Million In Venture Financing 11
NeuroGenetic Pharma Raises USD0.1 Million in Venture Financing 12
NeuroGenetic Pharma Raises US$0.2 Million In Venture Financing 13
NeuroGenetic Pharma Secures Investment In Venture Financing 14
NeuroGenetic Pharmaceuticals Inc, Key Competitors 15
NeuroGenetic Pharmaceuticals Inc, Key Employees 16

List of Figures
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NeuroGenetic Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[NeuroGenetic Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Atriva Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Atriva Therapeutics GmbH (Atriva Therapeutics) is a developer of antiviral therapies that develops therapies against seasonal and pandemic influenza. The company develops ATR-001 drug candidate, a MEK inhibitor which targets influenza. It also offers repurposing existing MEK inhibitors, orig …
  • Fresenius Kabi USA LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Fresenius Kabi USA LLC (Fresenius Kabi), a subsidiary of Fresenius Kabi AG, is a pharmaceutical and medical device company which provides lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. It provides products and services to critically and chronically il …
  • GW Pharmaceuticals Plc (GWP)-製薬・医療分野:企業M&A・提携分析
    Summary GW Pharmaceuticals plc (GW Pharmaceuticals) is a biopharmaceutical company which discovers, develops and commercializes innovative therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, f …
  • Nativis Inc-医療機器分野:企業M&A・提携分析
    Summary Nativis Inc (Nativis) is a clinical stage bio-electronics company. Its portfolio of pipeline candidates which are under development for various therapeutic areas include recurrent glioblastoma, brain metastisis, pain, rheumatoid arthritis, lung cancer and melanoma. The company’s lead product …
  • Flexion Therapeutics Inc (FLXN):企業の財務・戦略的SWOT分析
    Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Aurobindo Pharma Ltd (AUROPHARMA):企業の財務・戦略的SWOT分析
    Aurobindo Pharma Ltd (AUROPHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Kering SA:企業の戦略・SWOT・財務情報
    Kering SA - Strategy, SWOT and Corporate Finance Report Summary Kering SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Sinopac Financial Holdings Company Limited:企業の戦略・SWOT・財務分析
    Sinopac Financial Holdings Company Limited - Strategy, SWOT and Corporate Finance Report Summary Sinopac Financial Holdings Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • KeyCorp:企業の戦略・SWOT・財務情報
    KeyCorp - Strategy, SWOT and Corporate Finance Report Summary KeyCorp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Saudi Industrial Export Company (4140):企業の財務・戦略的SWOT分析
    Summary Saudi Industrial Export Company (SIEC) is a chemical providing company that imports, exports and sales specialty chemicals, fertilizers, industrial materials and commodities. The company's fertilizers include diammonium phosphate, sulphur, urea, triple super phosphate, granular triple super …
  • Saudi Industrial Investment Group (2250):企業の財務・戦略的SWOT分析
    Summary Saudi Industrial Investment Group (SIIG) is a petrochemical company that invests, improves and develops petrochemical industry. The company produces ethylene, polyethylene, hexene, polypropylene and polystyrene. It also provides benzene, propylene, cyclohexane, motor gasoline blend, and hydr …
  • Banco Cooperativo Espanol S.A.:企業の戦略・SWOT・財務分析
    Banco Cooperativo Espanol S.A. - Strategy, SWOT and Corporate Finance Report Summary Banco Cooperativo Espanol S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Uponor Oyj:企業の戦略・SWOT・財務情報
    Uponor Oyj - Strategy, SWOT and Corporate Finance Report Summary Uponor Oyj - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Emory University-製薬・医療分野:企業M&A・提携分析
    Summary Emory University (Emory) is an educational service provider that offers academic degrees and programs through its arts colleges and graduate and professional schools. The university offers degree programs in the areas of business, law, medicine, nursing, public health, theology, and online c …
  • GS Engineering & Construction Corp (006360):企業の財務・戦略的SWOT分析
    GS Engineering & Construction Corp (006360) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Neptune Technologies & Bioressources Inc:企業のM&A・事業提携・投資動向
    Neptune Technologies & Bioressources Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Neptune Technologies & Bioressources Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed …
  • Regulus Therapeutics Inc (RGLS)-医療機器分野:企業M&A・提携分析
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a developer of microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target microRNAs. Its products are used for the ther …
  • Tata Steel Group:企業のM&A・事業提携・投資動向
    Tata Steel Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tata Steel Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Naked Wines plc (WINE):企業の財務・戦略的SWOT分析
    Naked Wines plc (WINE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Ducommun Incorporated:企業の戦略・SWOT・財務情報
    Ducommun Incorporated - Strategy, SWOT and Corporate Finance Report Summary Ducommun Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆